Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

Krazati and Erbitux show significant efficacy in KRAS G12C-mutant mCRC, with ORR of 34% (BICR) and 43% (investigator review). The disease control rate was 85% (BICR) and 86% (investigator review), ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

KRAS G12C mutations, present in approximately 13% of lung adenocarcinoma cases, are associated with limited responses to current KRAS G12C inhibitor treatments such as adagrasib and sotorasib, with ...

摘要本文针对2024年国内外晚期非小细胞肺癌（NSCLC）取得的临床进展进行回顾。在靶向治疗领域，特别是针对罕见突变的研究，继EGFR、ALK、ROS1等突变后的新靶点，KRAS ...

2025年，全球医药领域将迎来一系列重要趋势和突破性进展。在肿瘤学、肥胖症药物以及人工智能（AI）应用的推动下，药物创新的格局正在被重新塑造，医疗健康产业也将面临前所未有的机遇与挑战。近期，《自然》旗下的Nature Reviews Drug ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Global markets have recently experienced a mix of volatility and growth, with U.S. stocks facing challenges from competitive pressures in the AI sector and political uncertainties surrounding tariffs, ...